glp-1 prescriptions growth slowing 2024 Monitoring Report: RA Prescribing Trends - June Data GLP-1 Receptor Agonist Market Growth

When tirzepatide and niacin are used concurrently, several important safety considerations warrant attention: Tirzepatide-specific safety concerns: Boxed warning : Risk of thyroid C-cell tumors

Mina Tadrous, PharmD, PhD, professor of pharmacy at the University of Toronto, points to several other factors that weigh in injectables favor

It's difficult to compare danuglipron's efficacy with that of other oral GLP-1s due to differing patient populations and the lack of longer-term data on the drug

In SURMOUNT-1, 72 weeks of tirzepatide induced mean WL of 1622.5% in people without diabetes compared to 2.4% with placebo, with no sign of the weight plateauing, suggesting that there may be further WL with long-term use [46]

However, this raises the already pricey $1 price per serving to $2 per day

Griseofulvin Cmax increased by 37% while median Tmax did not change